All In MedTech

Device Trial Radar · NCT03859830

Clinical Observation of the Performance of Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line in Treatments of Patients With End-Stage Renal Disease (ESRD)

Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

276

Actual

Start

Jan 22, 2019

Primary completion

Nov 9, 2019

Study completion Nov 9, 2019

Sponsor

Lead sponsor
Vantive Health LLCNot on our public-company list
Sponsor type
Industry
Collaborators
Baxter Healthcare Corporation
First posted
Mar 1, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The incidence and prevalence of chronic kidney disease are increasing worldwide, as is the number of patients progressing to End-Stage Renal Disease (ESRD). China has experienced an increased accessibility and affordability of dialysis treatment, which in turn has brought about an increase in the number of patients receiving Renal Replacement Therapy (RRT).Without RRT, either in the form of maintenance dialysis or transplantation, ESRD is fatal. The scope of the trial is to observe the performance of Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line versus AK 200 Ultra S, extracorporeal circulation conduct of blood purification apparatus and Ultra Steriset as the comparator devices in treatment of patients using hemodialysis (HD) or hemodiafiltration (HDF) for ESRD.

Conditions

  • End-Stage Renal Disease

Interventions

  • Artis Dialysis System, ArtiSet PrePost and Ultra HDF LineDevice

    The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.

  • AK200 Ultra S, extracorporeal circulation conduct of blood purificationDevice

    The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants successfully completing HDF without interruption of therapy during DialysisTime frame: Day 1 (One Midweek HDF Treament Session, 4 hour duration)
  2. Number of Participants by Level of Effectiveness of Disposable Tubing during and after DialysisTime frame: Day 1 (One Midweek HDF Treament Session, 4 hour duration)
  3. Reduction ratio of β2-Microglobulin during and after DialysisTime frame: Day 1 (One Midweek HDF Treament Session, 4 hour duration)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site

    Beijing, Beijing Municipality, China

  • Investigational Site

    Foshan, Guangdong, China

  • Investigational Site

    Wuhan, Hubei, China

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.